演讲者简历

Engineering Bispecifics

Yoram Reiter, PhD, Head Laboratory of Molecular Immunology Technion-Israel Institute of Technology

Yoram Reiter is a Professor and the Sebba chair in Sciences at the faculty of Biology Technion-Israel Institute of Technology. He heads the Laboratory of Molecular immunology and is also the director of the Lokey Interdisciplinary Center for Life Sciences and Engineering at the Technion. Reiter’s lab develops new approaches for cancer immunotherapy and other molecular engineering approaches for autoimmunity using recombinant antibodies and MHC molecules. Reiter published >100 scientific papers and reviews as well as >30 patents in the fields of antibody engineering, immunotherapy, and molecular immunology. He is the co-founder of AIT - Applied Immune Technologies which develops T cell receptor like antibodies for clinical applications. AIT was aquired by Adicet Bio (CA, USA) and merged company raised >$million50 from Orbimed and Novartis VCs.

Christoph Spiess, PhD, Senior Scientist, Antibody Engineering, Genentech, Inc.

Christoph Spiess received his PhD from the University of Konstanz (Germany). After completing his postdoctoral studies in the field of protein folding at Stanford University, he joined Genentech in 2007 and is currently a senior scientist in the Department of Antibody Engineering. His group is involved in the development of technologies to identify and produce bispecific antibodies for research and clinical development.

Nathan Trinklein, PhD, VP, Teneobio

Dr. Trinklein is currently Vice President of Discovery at Teneobio. His group employs a novel sequence-based approach for antibody discovery that leverages next-gen sequence and high-throughput recombinant expression to screen large numbers of diverse sequence-defined antibodies. Prior to Teneobio, Dr. Trinklein was co-founder and CEO of SwitchGear Genomics, a venture-backed company that was acquired in 2013. SwitchGear developed and commercialized a unique cell-based platform for small molecule pathway screening. Dr. Trinklein served as the Technical Director of the Stanford ENCODE project and received his Ph.D from Stanford University. Dr. Trinklein has published over 20 peer-reviewed papers and is an inventor on over 15 patents.

James Legg, PhD, VP, Research and Development, Crescendo Biologics

James Legg is currently VP Research and Development at Crescendo Biologics in Cambridge UK where he is responsible for Crescendo's building portfolio of Immuno Oncology Humabody Biologics. Prior to joining Crescendo, James completed a Ph.D in Molecular Cell Biology from Imperial College London and a Post Doc at Imperial Cancer Research Fund (now CRUK) before moving into the Biotechnology industry with a role at Cambridge Antibody Technology and then a number of positions within MedImmune, the Biologics arm of AstraZeneca.

Christoph Goletz, PhD, Associate Director, Preclinical Pharmacology & Cancer Immunology, Glycotope GmbH

Christoph Goletz studied biology at the University of Konstanz and received his PhD at the “Freie Universität Berlin”. Since 2012 he is a leading scientist at Glycotope GmbH. As specialist in immunology he is currently responsible for the preclinical development of a bispecific immune checkpoint inhibitor.

Fabian Richter, PhD, Post-Doc, Biomedical Engineering, Cell Biology and Immunology, University of Stuttgart

Fabian Richter holds a Post-Doc position in the Biomedical Engineering Group at the Institute of Cell Biology and Immunology based at the University of Stuttgart (USTUTT), Germany. He studied Technical Biology at USTUTT and YALE University, CT, US and finished his PhD in 2015 back at the USTUTT. His current research focuses on the design and development of novel Immunoglobulin-based proteins with potential for therapeutic application.

Jose Munoz Olaya, PhD, Principal Scientist, Drug Discovery, F-star

Dr. Munoz-Olaya joined F-star in 2013 and currently holds the position of Principal Scientist within the Drug Discovery department, where he’s lead a number of internal and partnered projects. Prior to joining F-star, Dr Munoz-Olaya earned his PhD at the University of Barcelona where he studied novel therapies for the treatment of HIV-1.

Mark S. Dennis, PhD, Fellow, Denali Therapeutics

Building on 35 years of experience in protein and antibody engineering while a Principal Scientist at Genentech, Mark is currently a Fellow at Denali Therapeutics providing strategic direction and guidance for the development of protein therapeutics targeting neurological diseases. While at Genentech, Mark developed a practical method to deliver biotherapeutics across the blood-brain barrier, established that association with albumin could increase the serum half-life of biotherapeutics and was a key member of teams establishing early Antibody-drug conjugate (ADC) and T-cell Dependent Bispecific (TDC) technologies for oncology. Mark has authored over 60 papers and contributed to over 30 granted patents.

John Lofblom, PhD, Associate Professor, Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology

John Lofblom is an associate professor at KTH Royal Institute of Technology. His current research focus is on method development for directed evolution of affinity proteins, proteases and aggregation inhibitors as well as engineering of small affinity proteins into multimeric formats for new modes of action.

Martin Bader, PhD, Head, Biochemical and Analytical Research, Pharma Research and Early Development Roche

Martin obtained his PhD in Biochemistry from the University of Konstanz in a joint program with the University of Michigan at Ann Arbor. After postdoctoral training at the University of Washington in Seattle, Martin joined Mountain View-based Amunix to work on long-acting protein therapeutics. Martin then moved to Roche pRED as a group leader in the department of Downstream Processing and was subsequently promoted to Department Head of Biochemistry. In his current role as Head of Biochemical & Analytical Research, Martin leads a department with 90+ scientists involved in protein characterization and assay development from lead selection to the start of clinical studies. Under his leadership, the department has advanced multiple next generation antibodies from research into early development. As a member of the pRED Large Molecule Research leadership team, Martin is also responsible for the department’s digital and automation strategy.

Sophia N. Karagiannis, BA, MS, PhD, Reader, Translational Cancer Immunology, St. John’s Institute of Dermatology, School of Basic & Medical Biosciences, King's College London

Dr. Sophia Karagiannis is a Reader in Translational Cancer Immunology at King’s College London. She heads a cancer antibody discovery team focused on designing novel agents for skin, ovarian and breast cancers and striving to understand the cross-talk between patient immune cells and cancer. Major research streams in the Karagiannis laboratory include: a) dissecting B cell and antibody responses and understanding how these are modulated by the tumor microenvironment; b) interrogating patient humoral responses for potential biomarkers to aid stratification and to inform patient-focused treatments; c) designing Fc-modified antibodies with enhanced effector functions; d) elucidating the mechanisms of action of antibodies engineered with modified Fc regions and of different isotypes, namely IgG1, IgG4 and IgE, in disease-relevant models. The group are the first to design and translate an IgE class antibody recognizing a cancer antigen to a Phase I clinical trial in patients with solid tumours.

Rastislav Tamaskovic, PhD, Head, TC Facility, Senior Scientist, Biochemistry, University of Zurich

Dr. Rastislav Tamaskovic is head of TC facility at the Department of Biochemistry, University of Zurich. After completing PhD at the Paul Scherrer Institut (PSI), Switzerland, he joined as a postdoctoral fellow the Friedrich Miescher Institute (FMI) in Basel. Here he pioneered the work on tumor suppressor protein kinase NDR and postulated its function in cell cycle progression and mitotic exit network. He and his colleagues also unveiled - based on studies with knockout animals - the crucial role of PKB kinase in the maintenance of cell survival via counteracting p53-dependent apoptosis. In 2005, he joined Plückthun’s laboratory at the University of Zurich where he initiated the SCL project on next generation of tumor targeting of ErbB family receptors. Among other anti-tumor compounds, he and his coworkers invented the bispecific and biparatopic designed ankyrin repeat proteins (DARPins), a novel class of tumoricidal agents triggering a potent apoptotic response in ErbB2-overexpressing breast tumors.

Javier Chaparro-Riggers, PhD, Senior Director, Protein Engineering, Pfizer, Inc.

Rick Hibbert, MBA, PhD, Assistant Director, Protein Production and Chemistry, Genmab B.V.

Rick earned his D.Phil. in Biochemistry from Oxford University and an MBA from the Amsterdam Business School. He performed a Post-Doctoral Research Fellowship at the Netherlands Cancer Institute. He joined Genmab in 2013 and works as Assistant Director, responsible for the Protein Production & Chemistry department, CMC research and for projects related to Genmab’s proprietary DuoBody® bispecific antibody platform.

Advancing Bispecifics

Laurent Gauthier, PhD, Senior Director, Research and Development, Innate Pharma

I joined Innate Pharma (IPH) in 2002, currently as Senior Director in IPH Research laboratory. I received my doctorate degree in immunology from the Centre d’Immunologie de Marseille-Luminy (CIML-Aix-Marseille University - France) in 1998. I did my post-doctoral research at Laboratoire Architecture et Fonction des Macromolécules Biologiques (AFMB), a center of structural biology, in Dr Herman VanTilbeurgh’s team. Subsequently, I was a CNRS scientist at the CIML in Dr. Claudine Schiff’s team. I started at IPH as a team leader and project manager, concentrating on protein chemistry and antibody engineering. I participated to the development of all IPH assets including NK checkpoint inhibitor antibodies Lirilumab and Monalizumab. Since 2009, I have worked specifically as a director of the Antibody Department and head of NK cell engager program. I currently oversee a group of about 30 researchers. I have been an inventor on more than 25 patent publications.

Christina Furebring, PhD, SVP, Research, Alligator Bioscience

Dr. Furebring joined Alligator Bioscience in 2001, as a SVP Research she is responsible for the preclinical programs consisting of mono and bispecific antibodies for tumor directed immunotherapy of cancer . Dr. Furebring has more than 20 years of experience with protein and antibody optimization as well as generation of antibodies using phage display. Dr. Furebring completed her PhD in Immunotechnology from Lund University, Sweden.

Taylor H. Schreiber, M.D., PhD, Chief Scientific Officer, Shattuck Labs, Inc.

Dr. Schreiber is a physician/scientist with over a decade of experience developing immuno-oncology therapeutics. Taylor is the inventor of the Agonist Redirected Checkpoint (ARC) platform being developed by Shattuck Labs. Prior to Shattuck, he co-founded Pelican Therapeutics, which sprung from his work on the immunobiology of TL1A and TNFRSF25. Dr. Schreiber also served as Chief Scientific Officer of Heat Biologics, Inc., has published over 30 articles in prestigious peer-reviewed journals, and is the inventor on over a dozen patents.

Rakesh Dixit, PhD, VP, Safety Assessment, Medimmune, Inc.

Rakesh is a Vice President, R & D and the Global Head of the Biologics Safety Assessment comprising of Toxicology, Pathology and Laboratory Animal Resources functions where he is responsible for overseeing the biologics safety assessment of the entire MedImmune biologics portfolio in all therapeutics areas (2006-todate). Prior to joining MedImmune in 2006, Rakesh served as Senior Director of Toxicology in Johnson and Johnson and Associate Director-Research Fellow in Toxicology in Merck and Co., Inc. (1992-2005). Rakesh has over 25 years of experience in developing pharmaceutical and biotechnology-derived drugs and is the author of over 60 peer-reviewed scientific publications and has been invited to deliver Rakesh is regarded as a Key Opinion Leader in Toxicology community. Rakesh is the Editor-in-chief of Toxicology Mechanisms and Methods and an Associate Editor of Toxicology and Applied Pharmacology and Journal of Toxicology and Environmental Health- all key major toxicology journals.

Eric Smith, PhD, Director, Bispecific Antibodies, Regeneron, Inc.

Dr. Eric Smith received his Ph.D. in Microbiology and Immunology from Duke University in 1997. Following a postdoctoral fellowship at NYU he joined Regeneron in 2002 as a member of the Antibody and Trap Technologies group, where he worked on cytokine traps and related molecules. In 2008 he became a member of the Bispecific Antibodies team and is currently the Director of Bispecifics at Regeneron.

Marina Bacac, PhD, Head, Cancer Immunotherapy, Roche Innovation Center Zurich

Marina joined Roche in 2010 and currently heads one of the Cancer Immunotherapy Departments at the Roche Innovation Center Zurich (RICZ). Marina and her team are dedicated to the characterization of the activity of different anti-cancer therapeutic agents including Gazyva, T-cell bispecific antibodies (TCBs), immunocytokines and checkpoint immunomodulators. Marina also coordinates the discovery teams involved in the development of TCB programs in pre-clinical and clinical stage of development (CEA-TCB and CD20-TCB, both clinical development). She is also actively involved in the coordination of the Tumor Immunology Network established between Roche and several Academic Institutions and pioneers efforts focused on establishment of ex vivo cultures of fresh primary tumor explants for testing of cancer immunotherapy agents. Marina participates in building and overseeing Roche’s portfolio focused on antibody-based cancer immunotherapeutics.

Marina obtained her PhD in Oncology from the University of Trieste (Italy) in 2003 working on ruthenium-based anti-cancer drugs. She was awarded by the Marie Curie Fellowship to perform part of her PhD at the University of Leiden (Netherlands). Following the PhD, Marina moved to Lausanne (Switzerland) for the post-doctoral fellowship at the University Hospital Lausanne (CHUV) working on projects in the field of tumor-host interaction.

Ida Hiemstra, PhD, Lead Scientist, Translational Research, Genmab B.V.

Ida Hiemstra is an immunologist and infectious biologist by training. She studied at the Utrecht University, with internships at the Immunotherapy laboratory of the Wilhelmina Children’s Hospital in Utrecht and the microbiology department at the San Diego State University in California. She continued her PhD at the VU University Medical Center in Amsterdam investigating mucosal immunology. She worked as a postdoc for three years at the Dutch Blood Supply foundation in Amsterdam investigating myeloid-derived suppressor cells, after which she joined Genmab as a translational research scientist in September 2016. Ida is the Lead Translational Research Scientist on Genmab’s DuoBody-CD3xCD20 program.

Catherine J McMahan, PhD, Senior Director, Pharmacology and Cell Sciences Research and Non-Clinical Development, Aptevo Therapeutics

David Szymkowski, PhD, VP, Cell Biology, Xencor

David Szymkowski leads the immunology group as vice president of cell biology at Xencor, Inc. Xencor is a clinical-stage biopharmaceutical company developing Fc-engineered and bispecific antibodies and cytokine mimetics for the treatment of autoimmune diseases, allergic diseases, and cancer. Currently, 12 candidates engineered with Xencor's XmAb technology are in clinical development internally and with partners including Novartis, Amgen, Merck, Morphosys, Janssen, Boehringer Ingelheim, and Alexion. Prior to joining Xencor in 2002, Dr. Szymkowski was a principal scientist in the respiratory/inflammation group at Roche in Palo Alto, CA. Previously, he was a virology program leader at Roche in the U.K. He received his B.A. at Johns Hopkins University and his Ph.D. in molecular and cell biology from Penn State, and completed a postdoc at the Imperial Cancer Research Fund (U.K.).

Anika Jäkel, PhD, Director, Preclinical Pharmacology & Cancer Immunology, Glycotope GmbH

Anika Jäkel is a specialist in immunology and joined Glycotope GmbH in 2016. Her work focus lies on the pharmacological in vitro and in vivo assessment of bispecific antibody constructs designed to target and treat solid tumors. Recently, Anika became a leading scientist and is now responsible for the Preclinical Pharmacology & Cancer Immunology group at Glycotope with its broad pipeline on bispecific immunotherapeutics. Before her appointment at Glycotope, Anika acquired competent knowledge on the complex immune cell network of mice and humans during her PhD and as a Postdoc in the Immune Defense Mechanisms group at the Robert Koch Institute.

Ekkehard Moessner, PhD, Head, Protein Engineering, Large Molecules Research, Roche Innovation Center Zurich

Graduated in chemistry, PhD im Molecular Biology; Postdoc in Antibody Engineering. Joined Glycart Biotechnology in 2003, which was acquired by Roche in 2005. Since then involvement in several projects of protein design, engineering and selection.

Virginie Nägele, PhD, Senior Scientist BiTE Technology Amgen Research (Munich) GmbH

Virginie Naegele, Ph.D., is a Senior Scientist at Amgen Research (Munich) GmbH. After studying biology at the Technical University of Munich she received her doctoral degree in the field of medical microbiology from the Technical University of Munich. Virginie has more than 6 years of experience in various fields of the BiTE® technology, focusing on the development of BiTE® antibody constructs from early stages to clinical development.

Tariq Ghayur, PhD, Distinguished Research Fellow, Foundational Immunology, AbbVie Bioresearch Center

Tariq Ghayur received his Ph.D (1987) in Immunology from McGill University, Montreal, Canada and did his post-doctoral training at McGill (1987-’88) and Dana Farber Cancer Institute (1988-’90). He joined AbbVie Inc. in 1990. Tariq has worked on both small molecule and therapeutic antibody discovery programs and from 1998-2004 led two therapeutic antibody discovery project teams and delivered 2 drug development candidates. From 2011-2016, Tariq led the dual variable domain Ig (DVD – Ig™) Initiative and the Novel Biologics group at AbbVie. Currently, he leads the Foundational Immunology group. In addition to therapeutic antibodies, novel biologic formats and antibody generation technologies, his areas of interest are inflammation, intracellular trafficking, antigen processing and presentation, lymphocyte biology, cytokine biology and glyco-biology.

Weon-Kyoo You, PhD, Head, R&D, VP, ABL Bio, Inc,

After I received my Ph.D. majored in Biochemistry at Yonsei University, South Korea, I have worked as a postdoctoral fellow at UC San Francisco, and as a researcher at Sanford-Burnham Prebys Medical Discovery Institute from 2004 to 2012 to expand my research experience and knowledge. I have successfully performed several research projects and published many papers regarding tumor-induced angiogenesis and tumor microenvironments, especially focusing on the efficacy of drug candidates using nonclinical animal models. After I came back to Korea, I was joined as a project leader in the drug development project to discover and develop a novel bispecific antibody at Hanwha Chemical, Biologics R&D center. Currently I am working as R&D Head at a new startup biotech company, ABL Bio, Inc, supervising and managing many exciting projects for antibody-based novel therapeutics.

Mihriban Tuna, PhD, Vice President, Drug Discovery, F-star

Mihriban has over 15 years’ experience in antibody engineering and discovery and has successfully managed a number of proprietary and collaborative drug discovery projects with big pharma. Prior to joining F-star, she worked in technology enhancement in Biopharm R&D at GlaxoSmithKline (GSK) and in the selection and optimisation of lead domain antibodies (dAbs) at Domantis Ltd. Mihriban holds a PhD in Biochemistry from University of Sussex, UK, and a BSc in Biology from Middle East Technical University, Turkey.

Marina Pavlidou, PhD, Project Leader, Discovery, Pieris Pharmaceuticals GmbH

Marina Pavlidou serves as a Project leader Discovery at Pieris Pharmaceuticals, GmbH. In this position she manages projects in the field of immuno-oncology from early discovery to IND. Marina joined Pieris in 2015 as group leader of the Selection Technologies group, being responsible for Anticalin® selection campaigns. Marina studied biology at the University of Tübingen and completed her PhD studies at the Research Center Jülich in the area of protein biochemistry. During her PhD and postdoctoral studies at the Research Center Jülich, Marina worked on the phage display selection and biophysical characterization of protein-based therapeutic agents.

Tumour Microenvironment

Christian Klein, PhD, Oncology Discovery & Translational Area, Cancer Immunotherapy Discovery, PRED, Roche Innovation Center, Zurich

Christian Klein, Distinguished Scientist is Head of Oncology Programs and Department Head Cancer Immunotherapy Discovery at the Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development, Switzerland specialized in the discovery, validation and preclinical development of antibody based Cancer Immunotherapy (CIT) and bispecific antibodies. During his >14 years at Roche he has made major contributions as research project leader to the development and FDA/EMA approval of GAZYVA/GAZYVARO (obinutuzumab, GA101), to the preclinical development of five bispecific antibodies currently in active clinical development: 1) anti-Ang-2/VEGF CrossMAb RG7221 (vanucizumab) in oncology (Ph II), 2) anti-VEGF/Ang-2 CrossMAb RG7716 in ophthalmology (Ph II), 3) CEA-IL2v immunocytokine RG7813 (Ph I), 4) CEA-CD3 T cell bispecific antibody (CEA TCB) RG7802 (Ph I), 5) FAP-IL2v immunocytokine RG7461 (Ph I), and lead the development of Roche’s novel bispecific antibody technologies e.g. the CrossMAb, immunocytokine and T cell bispecific antibody platforms. Since 2012 he his doing his “Habilitation” in Biochemistry at the Ludwig-Maximilians University (LMU) in Munich, Germany.

Dario Neri, PhD, Professor, Biomacromolecules, Chemistry and Applied Biosciences, ETH Zürich

Dario Neri studied Chemistry at the Scuola Normale Superiore of Pisa and earned a PhD in Chemistry at the Swiss Federal Institute of Technology (ETH Zürich), under the supervision of Professor Kurt Wüthrich. He then performed post-doctoral research at the Medical Research Council Centre in Cambridge (UK), under the supervision of Sir Gregory Winter. He has now been a Professor at the ETH Zürich since 1996. The research of the group Neri focuses on the engineering of therapeutic antibodies for the therapy of cancer and other angiogenesis-related disorders. Other research activities include the chemical proteomic discovery of novel vascular markers of pathology and the development of DNA-encoded chemical libraries. Dario Neri is a co-founder of Philogen (www.philogen.com), a Swiss-Italian biotech company which has brought five antibody-based products into multicenter clinical trials for the therapy of cancer and of rheumatoid arthritis. Dario Neri has published over 300 articles in peer-reviewed scientific journals. He is the recipient of the ISOBM Abbott Prize 2000, of the Amgen-Dompe’ Biotec Award 2000, of the Mangia d’Oro 2001, of the Prous Award 2006 of the European Federation of Medicinal Chemistry, of the Robert-Wenner-Prize 2007 of the Swiss Cancer League, of the SWISS BRIDGE Award 2008, of the Prix Mentzer of the French Medicinal Chemistry Society in 2011, of the Phoenix Prize 2014 and of an ERC Advanced Grant in 2015.

Onur Boyman, MD, Professor and Chair, Immunology University Hospital Zurich, University of Zurich

After obtaining his M.D. degree from the University of Zurich, Switzerland, Onur Boyman trained as a postdoctoral fellow at the Scripps Research Institute in La Jolla, California. He then joined the Division of Immunology and Allergology of the University Hospital of Lausanne, Switzerland, as principle investigator and clinical fellow, before receiving in 2010 a professorship of the Swiss National Science Foundation. Since 2014, Onur Boyman has been professor and chair of clinical immunology at the University of Zurich and director of the Department of Immunology at University Hospital Zurich. Research in his laboratory focuses on the modulation of immune responses using cytokine-directed approaches, such as particular IL-2 formulations to stimulate regulatory versus effector T cells for selective immunotherapy, as well as pro-inflammatory cytokines and their inhibitors in chronic inflammatory and autoimmune diseases.

Dmitry Gabrilovich, MD, PhD, Professor, Immunology, Microenvironment and Metastasis, The Wistar Institute

Dmitry Gabrilovich, MD, Ph.D., is currently a Christopher M. Davis Professor in Cancer Research and Program Leader, Immunology, Microenvironment, and Metastasis Program at the Wistar Institute in Philadelphia. He studied dendritic cell (DC) biology under Dr. Stella C. Knight at the Imperial College of London in the UK and was trained in cancer research at U.T. Southwestern Medical School and Vanderbilt University in the laboratory of Dr. D. Carbone. In mid 1990s his group demonstrated, that DCs in cancer were functionally impaired and have described the first tumor-derived factor directly implicated in DC defects in cancer. His group was the first that implicated lipid accumulation as one of the mechanisms negatively regulating function of DCs in cancer. Dr. Gabrilovich was one of the discoverers of myeloid-derived suppressor cells (MDSC). His group characterized number of molecular mechanisms regulating expansion and function of these cells. His group provided first evidence that MDSC can be therapeutically targeted in patients.

Mark Cragg, PhD, Professor, Experimental Cancer Biology, Antibody & Vaccine Group, University of Southampton

Mark Cragg is Professor of Experimental Cancer Biology in the Cancer Sciences Unit of Southampton University Faculty of Medicine. He obtained his PhD in 1998 and did his postdoctoral studies in Southampton with Martin Glennie and Melbourne, Australia with Andreas Strasser before returning to the UK to start his own group in 2007. He is interested in all aspects of how tumour regression can be induced and is focused on two main types of therapeutics – antibodies and small molecule inhibitors, with the aim of understanding how they elicit tumour cell destruction, how resistance occurs through changes in the microenvironment and how it might be overcome.

Marie H. Kosco-Vilbois, PhD, Chief Scientific Officer, Novimmune SA

CSO of Novimmune SA, responsible for overseeing the discovery and development of antibody-based drugs for the targeted treatment of inflammatory and rare diseases, immune-related disorders and cancer. Prior industry experience includes GlaxoWellcome, Serono and Roche, the latter as a scientific member of the Basel Institute for Immunology. Holds a doctorate in Immunology and Human Anatomy from the Medical College of Virginia, USA. Inventor on numerous patents and author of >150 publications in the fields of immunology and biopharmaceutical research.

Jeanette Leusen, PhD, Associate Professor, Translational Immunology, University Medical Center Utrecht

Dr. Jeanette Leusen, received her PhD in 1995 at the University of Amsterdam, The Netherlands. Since then she investigates therapeutic antibodies and their modes of action, both in vitro and in vivo using several mouse models. Within the immunotherapy group, a unique panel of Fc receptor knock-out and transgenic animals has been developed and obtained over the past decades. Supported by grants from KWF and AICR, Dr. Leusen’s lab has generated and characterized a new transgenic mouse reconstituting FcR expression but incapable of ADCC, the so-called NOTAM mouse. New insights were obtained for both antibody therapy, and also FcR-induced antigen presentation

Last but not least, Dr. Leusen strongly believes in IgA as a novel class of antibody for treatment of both malignant and infectious diseases. In 2013 she published for the first time in vivo efficacy of IgA antibodies, and more will follow soon.

Denise L. Faustman, MD, PhD, Director, Immunobiology, Massachusetts General Hospital, and Associate Professor, Medicine, Harvard Medical School

Denise Faustman MD, PhD is Director of the Immunobiology Laboratory at Massachusetts General Hospital (MGH) and Associate Professor at Harvard Medical School Her research objective is to introduce new therapeutic concepts to treat transplant rejection, autoimmune diseases and, more recently, cancer. She has been working in the fields of autoimmunity and immunology for nearly three decades, with a particular interest in identifying new biological processes that may be related to human disease and most frequently on the TNFR2 signaling pathway. In the Immunobiology Lab, I lead teams that work to uncover the basic molecular and immunological mechanisms behind human and murine immune pathogenesis as it relates to TNF and translate these new innovations to the clinic.

Gregory Driessens, PhD, Project Leader & Head, in vivo Pharmacology, iTeos Therapeutics

Gregory Driessens is project Leader for TIGIT program and group Leader of the in vivo pharmacology team at iTeos Therapeutics. He joined the company in 2013 with 12 years’ experience in immunology, immunotherapy and cancer biology. Grégory holds a MSc and Ph.D. in Biomedicals Sciences from ULB (Brussels). He was a post-doctoral fellow for three years in the lab of Thomas Gajewski (UChicago) before coming back to the lab of Cédric Blanpain (Brussels) to study cancer and cancer stem-cell biology. Grégory has authored 19 peer-reviewed publications and is the inventor of six patent applications.

Frederick Arce Vargas, MD, PhD, MRCS, Group Leader, Translational Research, Autolus

Dr. Arce Vargas obtained a medical degree in the University of Costa Rica. He then moved to the United Kingdom where he obtained a PhD working with Prof. Mary Collins in UCL, where he worked on cancer vaccines using genetically modified dendritic cells. Following his interest in cancer immunotherapy, he then joined the labs of Sergio Quezada and Karl Peggs in the UCL Cancer Institute where his work focused on immune modulatory antibodies. He has recently moved as a group leader in Translational Research in Autolus, where he is working in immunotherapy with CAR-T cells.

Yan Qu, PhD, Senior Principal Scientist, Rinat Pfizer

Pascal Merchiers, PhD, VP, R&D, Tusk Therapeutics Ltd.

Pascal Merchiers is Vice President of R&D at Tusk Therapeutics. He has over 15 years’ drug development experience and antibody expertise across a wide range of therapeutic areas and has held senior positions at IntroGene BV, Galapagos NV, Ablynx NV and Thrombogenics NV. Pascal has a Ph. D. in Medical sciences from the University of Leuven (Belgium).

Michael L. Meyers, M.D., PhD, Chief Medical Officer, Syndax Pharmaceuticals, Inc.

Philipp Mueller, PhD, Principal Scientist, Cancer Immunology & Immune Modulation, Boehringer Ingelheim Pharma GmbH & Co. KG

Dr. Philipp Müller received his PhD in Biochemistry from the University of Basel in 2009 (Biozentrum, Prof. Jean Pieters), with a major focus on the immunology of infectious diseases, immune cell signaling and in vivo models of immune cell function as well as development. During the last 9 years his research has been dedicated to cancer immunology and immunotherapy. He has worked on and published in high ranking journals on the immune-promoting properties of Antibody-Drug-Conjugates, bispecific antibody formats as well as agonistic antibodies, such as anti-CD40, and their therapeutic combination with immune-checkpoint blockade. Dr. Philipp Müller is currently leading a research/project team as Principal Scientist within the Cancer Immunology & Immune Modulation Department of Boehringer Ingelheim (Biberach an der Riß, Germany) with a major focus on next generation oncolytic viruses and novel cancer vaccine concepts.

Len Seymour, PhD, Professor, Gene Therapies, Oncology, University of Oxford

Len Seymour is Professor of Gene Therapy at the University of Oxford, where he specialises in the use of genetic engineering and virology in treatment of cancer. He leads a university research containing some twenty scientists with expertise across the spectrum of virology and cell and synthetic biology. In 2003, he was the Founding Chairman of the British Society for Gene and Cell Therapy, aiming to establish this new technology as a mainstream medical discipline. He has strong interests in both clinical and commercial translation of sciences and is a founding scientist of Psioxus Therapeutics, the Native Antigen Company and Oxford Genetics.

SC Bios

SC2: Making Antibody Libraries in Phage and Yeast

Andrew M. Bradbury, Ph.D., MB, CSO, Specifica Inc.

Andrew Bradbury was trained in medicine at the universities of Oxford and London, and subsequently practiced medicine for five years (one full time, and four part time) in the U.K. He received his Ph.D. (Cambridge University) in the MRC Laboratory of Molecular Biology under the guidance of Dr. Cesar Milstein. After his Ph.D. he spent 10 years in Italy: three years as a post doc in the CNR Institute of neurobiology, Rome, Italy; and seven years in Trieste, where he was first visiting professor, and subsequently tenured as assistant professor at the International School for Advanced Studies (SISSA, Trieste, Italy). He was a staff scientist and group leader at Los Alamos National Lab from July 1999 to June 2017, when he left to join Specifica, a startup he founded that specializes in antibody selections and selling unique antibody libraries. He has worked in the field of phage display and antibody engineering for 25 years, and has helped organize over forty international congresses and practical courses in this field, both in Europe and the U.S. He has published over 130 peer-reviewed articles, including a number of reviews and commentaries on phage display and antibody engineering. He is one of the founding members of “The Antibody Society”, and is on the editorial board of three journals.

SC3 Introduction to The Tumour Microenvironment and Response to Cancer Immunotherapy

Mark Cragg, PhD, Professor, Experimental Cancer Biology, Antibody & Vaccine Group, University of Southampton

Mark Cragg is Professor of Experimental Cancer Biology in the Cancer Sciences Unit of Southampton University Faculty of Medicine. He obtained his PhD in 1998 and did his postdoctoral studies in Southampton with Martin Glennie and Melbourne, Australia with Andreas Strasser before returning to the UK to start his own group in 2007. He is interested in all aspects of how tumour regression can be induced and is focused on two main types of therapeutics – antibodies and small molecule inhibitors, with the aim of understanding how they elicit tumour cell destruction, how resistance occurs through changes in the microenvironment and how it might be overcome.

Frederick Arce Vargas, MD, PhD, MRCS, Group Leader, Translational Research, Autolus

Dr. Arce Vargas obtained a medical degree in the University of Costa Rica. He then moved to the United Kingdom where he obtained a PhD working with Prof. Mary Collins in UCL, where he worked on cancer vaccines using genetically modified dendritic cells. Following his interest in cancer immunotherapy, he then joined the labs of Sergio Quezada and Karl Peggs in the UCL Cancer Institute where his work focused on immune modulatory antibodies. He has recently moved as a group leader in Translational Research in Autolus, where he is working in immunotherapy with CAR-T cells.

SC4 Mutation and Selection Strategies Beyond Affinity Optimisation

Brian Fennell, PhD, Senior principal Scientist, BioMedicine Design (BMD), Pfizer Dublin

Brian Fennell is a Senior Principal Scientist in the BioMedicine Design Group, at Pfizer Grange Castle, Dublin, Ireland. Brian is coming up on 11 years in the BMD group/Pfizer & his group is responsible for the discovery and molecular engineering of novel protein therapeutics to treat a wide spectrum of human diseases. Prior to joining Pfizer, Brian was awarded an IRCSET fellowship & worked as a Post-Doctoral researcher focusing on tubulin as a potential drug target in the malarial parasite Plasmodium falciparum at the Moyne Institute of Preventive Medicine, Trinity College Dublin. He obtained his Degree from University College Dublin (UCD) and PhD from the Trinity College Dublin (TCD). Brian has attended and presented at numerous scientific workshops & conferences & has published book chapters & original research in numerous journals such as The Journals of Molecular Biology, PNAS, Immunology, Molecular Biochemical Parasitology, Antimicrobial Chemotherapy and in mAbs

Fred Darmanin Sheehan, PhD, Senior Principal Scientist, Biomedicine Design Pfizer Dublin

Fred Sheehan is a Senior Principal Scientist in the BioMedicine Design Group, at Pfizer Grange Castle, Dublin, Ireland. Fred has been in his current role for just over 11 years, he runs a group of scientists within the BMD / Pfizer responsible for the discovery and molecular engineering of novel biotherapeutics using display technologies. Prior to joining Pfizer, Fred worked as a Post-Doctoral researcher in the Biomedical Diagnostics Institute focusing on the development of portable, user-friendly, and autonomous antibody-based diagnostic systems for human and animal healthcare. He obtained his PhD from Dublin City University (DCU). Fred has attended and presented at numerous scientific workshops & conferences & has published book chapters & original research in numerous journals.

SC8 Selection, Screening and Engineering for Affinity Reagents

Julia Neugebauer, Ph.D., Director, MorphoSys AG

Dr. Julia Neugebauer currently holds the position of Director and Leader Discovery Programs at the MorphoSys AG, where she heads a team responsible for antibody discovery projects including target validation, antibody selections, and functional in vitro and in vivo characterization up to lead selection. Prior to that position Julia Neugebauer worked at MorphoSys as Project Team Leader for Customer Collaboration Projects. Altogether she has more than 12 years of experience in the field of antibody discovery and engineering. Julia Neugebauer studied biochemistry at the University of Regensburg and at the New York University and earned a PhD from the Ludwig-Maximilians-Universität in Munich.

Birgit Dreier, PhD, Senior Scientist and Group Leader HT-BSF, Plückthun Lab, University of Zurich

Dr. Birgit Dreier has been Senior Scientist in the group of Prof. Dr. A. Plückthun at the Department of Biochemistry, University of Zurich, for more than 10 years and is responsible for the organization, optimization and selection of DARPin (Designed Ankyrin Repeat Proteins) and other scaffold binders and their validation. Here she recently expanded her focus and is leading the High Throughput-Binder Selection Facility (HT-BSF). Prior to this engagement she acquired a strong background in Phage Display using different protein scaffolds (e.g. Fab fragments and zinc finger domains) during her PhD at the Department of Genetics, University of Erlangen, and her postdoctoral training at The Scripps Research Institute, San Diego.

SC10 Engineering of Bispecific Antibodies

Nicolas Fischer, Ph.D., Head, Research, NovImmune SA

Nicolas Fischer obtained a PhD in Biology from the Department of Molecular Biology University of Geneva on the structure and function of photosynthetic complexes. As a postdoctoral fellow he joined the Group of Sir Greg Winter at the MRC Department of Molecular Biology in Cambridge UK to study protein folding and Antibody engineering using phage display. In 2001 he joined NovImmune and led several therapeutic antibody discovery programs that have reached clinical development stage. He is now heading the Research Department and developing next generation bispecific therapeutic antibodies.

Michela Silacci, Ph.D., Director, Discovery Research, Covagen AG, part of J&J

Michela Silacci is Director in Discovery Research at Covagen, one of the Janssen Pharmaceutical Companies of J&J. Since joining Covagen in 2009, Michela has been the discovery leader of several projects both in the field of Immunology and Oncology. At present she is responsible for Covagen’s discovery activities in the field of Immunology. Michela studied biochemistry and molecular biology at the ETH Zurich. After a short internship in the laboratories of Sir Gregory Winter at the MRC in Cambridge (UK), Michela Silacci joined the group of Prof. Dario Neri at the Institute of Pharmaceutical Sciences at ETH for her PhD thesis. Main focus of the thesis was the construction and validation of an antibody phage library for the isolation of therapeutic antibodies. After obtaining her Ph.D., she joined Roche Glycart where she worked for 3 years as a scientist in the protein engineering group.

Choose your language
Chinese
Japanese
Korean
English